IL150566A0 - Nucleic acids and polypeptides and nogo-receptor proteins - Google Patents

Nucleic acids and polypeptides and nogo-receptor proteins

Info

Publication number
IL150566A0
IL150566A0 IL15056601A IL15056601A IL150566A0 IL 150566 A0 IL150566 A0 IL 150566A0 IL 15056601 A IL15056601 A IL 15056601A IL 15056601 A IL15056601 A IL 15056601A IL 150566 A0 IL150566 A0 IL 150566A0
Authority
IL
Israel
Prior art keywords
nogo
receptor proteins
disclosed
polypeptides
nucleic acids
Prior art date
Application number
IL15056601A
Other languages
English (en)
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IL150566A0 publication Critical patent/IL150566A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/05Animals comprising random inserted nucleic acids (transgenic)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
IL15056601A 2000-01-12 2001-01-12 Nucleic acids and polypeptides and nogo-receptor proteins IL150566A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17570700P 2000-01-12 2000-01-12
US20736600P 2000-05-26 2000-05-26
US23637800P 2000-09-29 2000-09-29
PCT/US2001/001041 WO2001051520A2 (en) 2000-01-12 2001-01-12 Nogo receptor-mediated blockade of axonal growth

Publications (1)

Publication Number Publication Date
IL150566A0 true IL150566A0 (en) 2003-02-12

Family

ID=27390581

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15056601A IL150566A0 (en) 2000-01-12 2001-01-12 Nucleic acids and polypeptides and nogo-receptor proteins
IL150566A IL150566A (en) 2000-01-12 2002-07-03 Nucleic acids and polypeptides and nogo receptor proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL150566A IL150566A (en) 2000-01-12 2002-07-03 Nucleic acids and polypeptides and nogo receptor proteins

Country Status (27)

Country Link
US (1) US20020012965A1 (https=)
EP (2) EP2163561A1 (https=)
JP (1) JP4763207B2 (https=)
KR (1) KR100828058B1 (https=)
CN (1) CN100354307C (https=)
AT (1) ATE466882T1 (https=)
AU (1) AU784349C (https=)
BG (1) BG106907A (https=)
BR (1) BR0107613A (https=)
CA (1) CA2397199C (https=)
CZ (1) CZ20022438A3 (https=)
DE (1) DE60142023D1 (https=)
EA (1) EA008480B1 (https=)
EE (1) EE200200386A (https=)
ES (1) ES2341842T3 (https=)
GE (1) GEP20063830B (https=)
HK (1) HK1051543A1 (https=)
HU (1) HUP0203863A3 (https=)
IL (2) IL150566A0 (https=)
IS (1) IS6455A (https=)
MX (1) MXPA02006885A (https=)
NO (1) NO20023387L (https=)
NZ (2) NZ520065A (https=)
PL (1) PL356887A1 (https=)
SK (1) SK9992002A3 (https=)
WO (1) WO2001051520A2 (https=)
YU (1) YU53502A (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066041A1 (en) 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
US7723488B2 (en) 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
US7371836B2 (en) 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US20020072493A1 (en) * 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins
US7119165B2 (en) * 2000-01-12 2006-10-10 Yale University Nogo receptor-mediated blockade of axonal growth
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
NZ525422A (en) 2000-10-06 2006-09-29 Biogen Idec Inc Isolated polynucleotides comprising a nucleic acid which encodes a polypeptide which modulates axonal growth in CNS neurons
GB0101313D0 (en) * 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
GB0101312D0 (en) 2001-01-18 2001-02-28 Glaxo Group Ltd Assay
JP2005507246A (ja) * 2001-08-27 2005-03-17 ノバルティス アクチエンゲゼルシャフト Nogoレセプターホモログおよびそれらの使用
US7309485B2 (en) * 2001-12-03 2007-12-18 Children's Medical Center Corporation Reducing myelin-mediated inhibition of axon regeneration
FR2841261B1 (fr) * 2002-06-25 2004-08-27 Univ Pasteur Compositions et methodes pour detecter les pathologies affectant la transmission neuromusculaire
EP1534736B1 (en) * 2002-08-10 2010-06-02 Yale University Nogo receptor antagonists
PT1534736E (pt) 2002-08-10 2010-09-07 Univ Yale Antagonistas do receptor nogo
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
CN1745094A (zh) * 2002-12-06 2006-03-08 新加坡综合医院有限公司 肽,其抗体,以及它们在中枢神经系统损伤的治疗中的用途
US7842666B2 (en) * 2002-12-20 2010-11-30 Research Foundation Of City University Of New York Inhibitors of myelin-associated glycoprotein (MAG) activity for regulating neural growth and regeneration
WO2004085648A2 (en) 2003-03-19 2004-10-07 Biogen Idec Ma Inc. Nogo receptor binding protein
US7541335B2 (en) 2003-04-04 2009-06-02 University Of Rochester Nogo-receptors and methods of use
EP1615654A2 (en) * 2003-04-16 2006-01-18 Yale University Nogo-receptor antagonists for the treatment of conditions involving amyloid plaques
AU2004247018A1 (en) * 2003-05-15 2004-12-23 Bayhill Therapeutics, Inc. Novel immunomodulating peptide
EP3514238B1 (en) * 2003-05-16 2021-05-05 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
GB0321997D0 (en) * 2003-09-19 2003-10-22 Novartis Ag Organic compound
WO2005059515A2 (en) * 2003-12-16 2005-06-30 Children's Medical Center Corporation Method for treating neurological disorders
US8912144B2 (en) * 2003-12-16 2014-12-16 Children's Medical Center Corporation Method for treating stroke via administration of NEP1-40 and inosine
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
CA2576193A1 (en) 2004-08-03 2006-02-16 Biogen Idec Ma Inc. Taj in neuronal function
WO2006047049A2 (en) * 2004-10-01 2006-05-04 Yale University Nogo-a polypeptide fragments, variant nogo receptor-1 polypeptides, and uses thereof
US20090137484A1 (en) * 2004-12-01 2009-05-28 National University Of Singapore Neuronal Network-Interacting Peptide
US7893032B2 (en) 2005-07-07 2011-02-22 Yale University NgR variants and compositions thereof for suppressing axonal growth inhibition
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク. コンドロイチナーゼabci変異体を用いた組成物およびその使用方法
CA2913655A1 (en) 2006-01-27 2007-08-09 Biogen Ma Inc. Nogo receptor antagonists
JP2009538282A (ja) * 2006-05-15 2009-11-05 バイオジェン・アイデック・エムエイ・インコーポレイテッド 乏突起膠細胞の生存を促進させるためのNogo受容体−1(NgR1)アンタゴニストの使用
JP2009544703A (ja) 2006-07-24 2009-12-17 バイオジェン・アイデック・エムエイ・インコーポレイテッド Sp35またはTrkAアンタゴニストの投与により髄鞘形成、ニューロンの生存および希乏突起膠細胞の分化を促進するための方法
MX2009005361A (es) 2006-11-21 2009-06-05 Abbott Lab Anticuerpos monoclonales neutralizantes contra el receptor de nogo-66 (ngr) y usos de los mismos.
EP2276500A4 (en) 2008-03-13 2015-03-04 Univ Yale REACTIVATION OF AXON GROWTH AND AXON RECOVERY IN CHRONIC REVERSE MARKET INJURIES
CL2009001155A1 (es) * 2008-05-13 2010-06-04 Genentech Inc Anticuerpo anti-pirb/lilrb aislado; polinucleotido que lo codifica; vector; celula huesped; metodo de obtencion; composicion farmaceutica que lo comprende; kit; y su uso para tratar enfermedades neurodegenerativas.
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
CN104470541A (zh) 2012-05-14 2015-03-25 比奥根艾迪克Ma公司 用于治疗涉及运动神经元的疾患的lingo-2拮抗剂
CN104935294B (zh) * 2014-03-20 2018-07-20 晶宏半导体股份有限公司 振荡器
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Lingo‐1拮抗薬及び脱髄障害の治療のための使用
CN105061560B (zh) * 2015-07-17 2018-10-09 暨南大学 一种Nogo-A受体结合肽及其衍生物与应用
CN113527462B (zh) * 2020-04-22 2023-05-23 北京大学 一种具有镇痛作用的小分子肽及其特异性抗体

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4839288A (en) 1986-01-22 1989-06-13 Institut Pasteur Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US5466585A (en) 1986-04-15 1995-11-14 Ciba-Geigy Corporation Interferon-induced human protein in pure form, monoclonal antibodies thereto, and test kits containing these antibodies
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
CA1315719C (en) 1988-02-05 1993-04-06 Arthur Bank Retroviral packaging cell lines and processes of using same
CA1339354C (en) 1988-09-01 1997-08-26 The Whitehead Institute For Biomedical Research Recombinant retroviruses with amphotropic and ecotropic host ranges
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
DE68923362T2 (de) 1988-11-04 1996-03-28 Zuerich Erziehungsdirektion Wachstumsregelfaktoren für neuriten.
US5250414A (en) 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
ATE273386T1 (de) 1991-09-20 2004-08-15 Hutchinson Fred Cancer Res Menschliches cyclin e
EP0620849B1 (en) 1992-01-07 2003-06-25 Elan Pharmaceuticals, Inc. Transgenic animal models for alzheimer's disease
US5733720A (en) 1992-06-18 1998-03-31 Washington University Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
WO1994017831A1 (en) 1993-02-11 1994-08-18 Erziehungsdirektion Of The Canton Zurich A combination of neurotrophin and antibody directed toward myelin-associated neurite growth inhibitory protein promotes central nervous system regeneration
FR2705361B1 (fr) 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
DK75393D0 (da) 1993-06-24 1993-06-24 Symbicom Ab Production of protein
ATE424927T1 (de) 1993-10-28 2009-03-15 Houston Advanced Res Ct Mikrofabriziertes poröses durchflussgerät zur diskreten bestimmung von bindungsreaktionen
MX198456B (es) 1994-03-09 2000-09-05 Abbott Lab Animales trangenicos que producen oligosacaridos y glucoconjugados.
FR2718329B1 (fr) 1994-03-21 2002-09-20 Rhone Poulenc Rorer Sa Lapin transgénique sensibilisé aux dyslipoprotéinémies.
US5908969A (en) 1994-05-13 1999-06-01 The Regents Of The University Of California Method of detecting prions in a sample and transgenic animal used for same
WO2000073452A2 (en) * 1999-06-02 2000-12-07 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
US5961976A (en) 1996-06-03 1999-10-05 United Biomedical, Inc. Antibodies against a host cell antigen complex for pre- and post-exposure protection from infection by HIV
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
WO2000053756A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999066041A1 (en) * 1998-06-16 1999-12-23 Human Genome Sciences, Inc. 94 human secreted proteins
WO2000070050A1 (en) * 1999-05-14 2000-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2311640A1 (en) * 1997-12-03 1999-06-10 Genentech, Inc. Polypeptides and nucleic acids encoding the same
JP3868740B2 (ja) * 1998-03-10 2007-01-17 ジェネンテック・インコーポレーテッド 新規なポリペプチド及びそれをコードする核酸
AU762055B2 (en) * 1998-03-10 2003-06-19 Genentech Inc. Novel polypeptides and nucleic acids encoding the same
AU3134799A (en) 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
CA2324297A1 (en) * 1998-04-23 1999-10-28 Genentech, Inc. Sh2 domain-containing peptides
CA2326001A1 (en) * 1998-04-24 1999-11-04 Genentech, Inc. Fizz proteins
AU761340B2 (en) * 1998-06-02 2003-06-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CZ304224B6 (cs) * 1998-11-06 2014-01-15 Schwab Monoklonální protilátka
KR100529270B1 (ko) * 1998-12-01 2005-11-21 제넨테크, 인크. 혈관신생 및 심혈관형성의 촉진 또는 억제
JP3993746B2 (ja) * 1998-12-22 2007-10-17 ジェネンテック・インコーポレーテッド 腫瘍性細胞成長阻害のための組成物及び方法
CA2362427A1 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2383592A1 (en) * 1999-03-31 2000-10-05 Curagen Corporation 2384891 acids including open reading frames encoding polypeptides; orfx
WO2001009162A2 (en) * 1999-07-30 2001-02-08 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
IL150566A0 (en) * 2000-01-12 2003-02-12 Univ Yale Nucleic acids and polypeptides and nogo-receptor proteins

Also Published As

Publication number Publication date
IS6455A (is) 2002-07-03
NZ520065A (en) 2006-02-24
ES2341842T3 (es) 2010-06-29
CN1404488A (zh) 2003-03-19
JP4763207B2 (ja) 2011-08-31
AU784349C (en) 2006-09-28
KR20020097157A (ko) 2002-12-31
CN100354307C (zh) 2007-12-12
CZ20022438A3 (cs) 2002-10-16
HUP0203863A3 (en) 2008-03-28
EE200200386A (et) 2003-12-15
PL356887A1 (en) 2004-07-12
WO2001051520A9 (en) 2002-07-18
HK1051543A1 (zh) 2003-08-08
CA2397199C (en) 2013-12-24
HUP0203863A2 (hu) 2003-03-28
EP2163561A1 (en) 2010-03-17
US20020012965A1 (en) 2002-01-31
EP1248803A2 (en) 2002-10-16
NO20023387D0 (no) 2002-07-12
SK9992002A3 (en) 2003-05-02
KR100828058B1 (ko) 2008-05-09
NZ541694A (en) 2006-08-31
WO2001051520A3 (en) 2002-04-18
DE60142023D1 (de) 2010-06-17
IL150566A (en) 2008-03-20
BR0107613A (pt) 2002-11-19
WO2001051520A2 (en) 2001-07-19
EA200200755A1 (ru) 2002-12-26
AU784349B2 (en) 2006-03-16
CA2397199A1 (en) 2001-07-19
MXPA02006885A (es) 2004-04-05
ATE466882T1 (de) 2010-05-15
EA008480B1 (ru) 2007-06-29
NO20023387L (no) 2002-09-11
YU53502A (sh) 2005-11-28
BG106907A (bg) 2003-05-30
EP1248803B1 (en) 2010-05-05
GEP20063830B (en) 2006-05-25
AU2940101A (en) 2001-07-24
JP2003519481A (ja) 2003-06-24

Similar Documents

Publication Publication Date Title
IL150566A0 (en) Nucleic acids and polypeptides and nogo-receptor proteins
WO2003031462A3 (en) Nogo receptor-mediated blockade of axonal growth
AU1153902A (en) Nogo receptor homologs
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
NZ270659A (en) Mammalian protein which binds to a gst-fkbp-rapamycin complex, dna therefor and diagnostic compositions
AU1922101A (en) Human fgf-21 gene and gene expression products
BR0009505A (pt) Compostos e processos para terapia e diagnóstico de câncer de pulmão
WO1998049300A3 (en) Truncated vegf-related proteins
WO1998021972A3 (de) Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender aktivität
DE69835680D1 (de) Therapeutische verwendung von smr1 protein und seinen aktiven derivaten
ATE300619T1 (de) Humane checkpointkinase, hcds1, zusammensetzungen und verfahren
WO2000077239A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2001008635A3 (en) Calcium channel transport polynucleotides, polypeptides, and antibodies
WO2000065028A3 (en) TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
UA72875C2 (uk) БІЛКИ, ЯКІ ЗВ'ЯЗУЮТЬСЯ З <font face="Symbol">b</font>-АМІЛОЇДНИМ ПЕПТИДОМ ТА ПОЛІНУКЛЕОТИДИ, ЩО ЇХ КОДУЮТЬ
WO2000061774A3 (en) Bone morphogenic proteins
DE69328060D1 (de) Angiotensin-II Typ-1 Rezeptor und dessen Herstellung
WO2001000638A3 (en) Novel genes encoding proteins having diagnostic, preventive, therapeutic, and other uses
WO2002061086A3 (en) Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1
WO2000042165A3 (en) Bone marrow-specific protein
WO1999046381A3 (en) Human fgf gene and gene expression products
WO2002052011A3 (en) A novel human leucine-rich repeat containing protein expressed predominately in bone marrow, hlrrbm1
WO2002000834A3 (fr) Nouveau polypeptide, proteine phosphatase humaine 9.68, et polynucleotide codant ce polypeptide
WO2002074959A3 (en) Human leucine-rich repeat containing protein expressed predominately in nervous system tissues, hlrrns1
WO2003044160A3 (en) Novel molecules of the card related protein family and uses thereof

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed